CDK1 and neoplasm: To assess the impact of MTT and SSA treatment on signaling pathways related to tumor progression, we assessed alterations in ERK, phospho-ERK, PCNA, CDK1 and cyclin D1 for proliferation and cell cycle progression; AKT, phospho-AKT and PARP cleavage for survival and resistance to apoptosis; and phospho-RPS6 and eIF4E for tumor cell growth and protein synthesis, each in Bon1- (Fig 4) and QGP1 cells (S5 Fig) during treatment with lanreotide and MTT.